Intra-Cellular Therapies, Inc. , a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.
Intra Cellular Therapies stock last closed at $72.37, up 0.51% from the previous day, and has increased 16.43% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.29 percentage points. Intra Cellular Therapies stock is currently +59.05% from its 52-week low of $45.50, and -14.75% from its 52-week high of $84.89.
There are currently 96.81M shares of ITCI outstanding. The market value of ITCI is $7.01B. In the past 24 hours, 2.19M ITCI shares were traded.
How to Buy Intra Cellular Therapies Stock
Not sure how to invest in Intra Cellular Therapies stock? Here's how.
Decide where to buy Intra Cellular Therapies stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Intra Cellular Therapies stock.
Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
Fund your brokerage account: Choose your payment method and add your info.
Research Intra Cellular Therapies stock: The Intra Cellular Therapies ticker symbol is ITCI. Is Intra Cellular Therapies stock a good investment? Should you buy shares of ITCI? How do ITCI's underlying business fundamentals look? Do top analysts think Intra Cellular Therapies is a good buy? Why has ITCI's stock price moved recently? (Hint: Our stock market research tools can help you figure out if ITCI is a good stock to buy).
Place your ITCI trade: Decide if you will purchase ITCI shares at the current market price or use a limit order to buy ITCI stock at a specific price.
Keep an eye on your ITCI position: Create a watchlist to important updates regarding your position in Intra Cellular Therapies shares.
Step 1: Decide where to buy Intra Cellular Therapies stock
You need an online brokerage account to access the NASDAQ market and buy ITCI shares.
A brokerage account is an investment account that enables you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to global markets: From Tech to Utilities, New York to Shanghai — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create a brokerage account
Now that you've chosen the right brokerage, it's time to fill out some personal details so you are able to invest in ITCI today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Intra Cellular Therapies stock
After you have selected the best place to buy Intra Cellular Therapies stock, it's crucial to analyze their stock before you invest, so you actually understand the risk as well as the upside.
Overview of key ITCI info
ITCI Price
$72.37
1w %
9.85%
1y %
16.43%
5y %
470.74%
P/E
-49.57x
P/B
11.85x
P/S
14.94x
PEG
N/A
Revenue
$464.37M
Earnings
-$139.67M
Fore. Rev. Growth
36.36%
Fore. Earn. Growth
N/A
Market Cap
$7.01B
Next Earnings
May 2, 2024
Next Dividend
N/A
ITCI Zen Score
WallStreetZen was designed to help everyday investors perform more in-depth fundamental analysis.
ITCI has cash burn of 124468000. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than long-term liabilities on the ITCI balance sheet.
There are more short-term assets than short-term liabilities on the ITCI balance sheet.
ITCI has $499.69M in cash and short term investments. This is sufficient to cover its annual cash burn of $124.47M.
ITCI has a low debt to equity ratio of 0.23.
Cons:
ITCI profit margin has gone up by 0.72 percentage points in the past year, but the company is still unprofitable.
Total ITCI debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Intra Cellular Therapies stock, according to Wall Street analysts?
Out of 10 Wall Street analysts who track ITCI, the consensus analyst rating on Intra Cellular Therapies is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent ITCI Analyst Ratings
Brian Abrahams, a top 5% analyst from RBC Capital reiterates ITCI with a buy rating and maintains their ITCI price target from $86.00 to $86.00, on Apr 3, 2024.
Charles Duncan, a top 5% analyst from Cantor Fitzgerald reiterates ITCI with a strong buy rating and maintains their ITCI price target from $101.00 to $101.00, on Feb 23, 2024.
Sumant Kulkarni, a bottom 6% analyst from Canaccord Genuity maintains ITCI with a strong buy rating and lowers their ITCI price target from $101.00 to $100.00, on Feb 23, 2024.
Graig Suvannavejh, a bottom 3% analyst from Mizuho maintains ITCI with a strong buy rating and raises their ITCI price target from $76.00 to $82.00, on Feb 16, 2024.
Mizuho's Graig Suvannavejh raised their price target on Intra Cellular Therapies (NASDAQ: ITCI) by 7.9% from $76 to $82 on 2024/02/17. The analyst maintained their Strong Buy rating on the stock.
In a Biotechnology sector review note ahead of the 2024/02/22 release of Intra Cellular Therapies' Q4 and FY 2023 earnings, Suvannavejh reported that their price target hike reflects Mizuho's updated models and revised 12-month price targets for names in the space.
Ashwani Verma, a bottom 30% analyst from Bank of America maintains ITCI with a strong buy rating and raises their ITCI price target from $74.00 to $82.00, on Jan 2, 2024.
Last year, ITCI revenue was $464.37M. In the last four year, ITCI's revenue has grown by 835.57% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 30.96%.
No, Intra Cellular Therapies doesn't provide an income stream by paying out dividends.
ITCI Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your ITCI trade
You have two primary options:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are usually sufficient.
Limit order: A limit order allows you to buy or sell a security at a specific price (or better). If you want to be sure you're buying or selling at a given dollar amount, use a limit order.
Press the Open button and your broker will execute your order.
If you require additional help investing in stocks on eToro, watch the how to video below:
How much does it cost to buy one Intra Cellular Therapies share?
As of Apr 19, 2024, it costs $72.37 to buy one share of Intra Cellular Therapies stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.138 shares of ITCI.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.